Name: MREO Cash Flow - Mereo Biopharma Group. Operating Cash & FCF | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Operating Cash Flow, Investing Cash Flow, Financing Cash Flow, Capital Expenditures, Free Cash Flow, Dividends Paid, Stock Buybacks, Net Change in Cash

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

MREO - Mereo Biopharma Group. PLC

USD | NASDAQ | Healthcare

MREO Cash Flow - Mereo Biopharma Group. Operating Cash & FCF | Ledgeburg

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23
Net Income
Net Income	(6.7)	(7.4)	(7.0)	(14.6)	(12.9)	(7.0)	(15.0)	(12.3)	(9.0)	(9.1)	(6.5)	(1.8)	(12.1)
Cash From Operating Activities
Depreciation & Amortization	0.0	-	-	-	0.0	(0.1)	0.1	0.1	0.0	(0.1)	0.1	0.1	0.0
Amortization Of Intangibles
Cash From Investing Activities
Capital Expenditures	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	-
Acquisitions
Cash From Financing Activities
Debt Issued	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt Repaid	-
Change In Cash & Equivalents
Effects Of Exchange Rate Changes	(0.2)	-	-	-	0.9	-	-	-	(0.1)	-	-	-	1.3
Net Change In Cash
Free Cash Flow
Free Cash Flow	(4.3)	-	-	-	(8.3)	-	-	-	(8.0)	-	-	-	-
Free Cash Flow To Equity	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	TTM	FY2025	FY2024	FY2023	FY2022
Net Income
Net Income	(35.7)	(41.9)	(43.3)	(29.5)	(42.2)
Cash From Operating Activities
Depreciation & Amortization	-	0.2	0.1	0.2	0.2
Amortization Of Intangibles	-	0.5	0.4	0.4	0.0
Stock-Based Compensation	-	7.6	7.4	4.9	4.8
Deffered Income Tax	-	-	0.0	0.0	0.0
Asset Impairments	-	-	-	-	-
Gains & Losses On Investments	-	-	-	-	-
Change In Accounts Receivable	-	-	-	-	-
Change In Inventory	-	-	-	-	-
Change In Accounts Payable	-	(1.4)	0.1	(1.3)	0.6
Change In Other Working Capital	-	-	-	-	-
Other Operating Activities	-	0.0	(1.8)	0.0	2.0
Cash From Operating Activities	-	(31.0)	(32.8)	(21.1)	(48.8)
Cash From Investing Activities
Capital Expenditures	-	0.0	0.0	0.0	0.0
Acquisitions	-	-	-	-	-
Divestitures	-	-
Cash From Financing Activities
Debt Issued	-	-	-	-	-
Debt Repaid	-	-	-	-	-
Common Stock Issuance	-	0.0
Change In Cash & Equivalents
Effects Of Exchange Rate Changes	-	1.9	(0.2)	2.8	(12.6)
Net Change In Cash	-	-	12.4	(10.8)	-
Cash Beginning Of Period	-
Free Cash Flow
Free Cash Flow	-	(31.0)	(32.8)	(21.1)	(48.8)
Free Cash Flow To Equity	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Cash Flow Statement